Ionis Pharmaceuticals (IONS) Non-Current Debt (2009 - 2025)

Ionis Pharmaceuticals' Non-Current Debt history runs 17 years deep, the most recent figure standing at $28.1 million for Q4 2025.

• On a quarterly basis, Non-Current Debt fell 45.85% year-over-year to $28.1 million in Q4 2025; TTM through Dec 2025 was $28.1 million, a 45.85% decrease from a year earlier, with the FY2025 full-year figure at $28.1 million, down 45.85% from the prior year.
• Non-Current Debt eased to $28.1 million in Q4 2025 per IONS's latest filing, from $51.9 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $60.0 million in Q1 2021 and bottomed at $8.8 million in Q1 2023.
• The 5-year median for Non-Current Debt is $25.4 million (2022), against an average of $32.2 million.
• Across the five-year window, Non-Current Debt tumbled 73.25% in 2022 and soared 161.92% in 2023, its largest moves.
• Year by year, Non-Current Debt stood at $59.7 million in 2021, then tumbled by 73.25% to $16.0 million in 2022, then surged by 161.92% to $41.8 million in 2023, then increased by 24.11% to $51.9 million in 2024, then sank by 45.85% to $28.1 million in 2025.
• Per Business Quant, the three latest IONS Non-Current Debt figures stand at $28.1 million (Q4 2025), $51.9 million (Q4 2024), and $41.8 million (Q4 2023).